期刊文献+

盐酸帕洛诺司琼在预防乳腺癌FEC方案化疗中恶心呕吐的疗效观察 被引量:2

The preventive effect of palonosetron hydrochloride on nausea and vomiting induced by breast cancer chemotherapy with cyclophosphamide,pharmorubicin and 5-fluorouracil
原文传递
导出
摘要 目的:采用盐酸帕洛诺司琼和盐酸托烷司琼来预防乳腺癌FEC方案辅助化疗引起的恶心、呕吐,并对其疗效进行观察。方法:选择需要辅助化疗的乳腺癌手术患者42例,术后统一采用FEC方案(氟尿嘧啶、表阿霉素、环磷酰胺)化疗,采用随机自身对照交叉设计方法,将42例患者随机分成AB、BA两组,AB组第一周期化疗前用盐酸帕洛诺司琼0.25mg止吐,第二周期用盐酸托烷司琼5mg止吐;BA组第一周期化疗前用盐酸托烷司琼5mg止吐,第二周期用盐酸帕洛诺司琼0.25mg止吐。每次化疗后1~4d观察患者的恶心、呕吐情况及其他不良反应。结果:42例患者中,使用盐酸帕洛诺司琼止吐时,化疗后24h内呕吐分级为0度25例,Ⅰ度13例,Ⅱ度3例,Ⅲ度1例,Ⅳ度0例;而使用盐酸托烷司琼止吐时,化疗后24h内呕吐分级为0度21例,Ⅰ度12例,Ⅱ度5例,Ⅲ度3例,Ⅳ度1例,两组差异有统计学意义(P<0.05)。使用盐酸帕洛诺司琼止吐化疗后24-96h内呕吐分级为0度20例,Ⅰ度14例,Ⅱ度7例,Ⅲ度1例,Ⅳ度0例;而使用盐酸托烷司琼止吐化疗后24~96h内呕吐分级为0度13例,Ⅰ度15例,Ⅱ度9例,Ⅲ度4例,Ⅳ度1例,两组差异有统计学意义(P<0.01)。使用盐酸帕洛诺司琼与盐酸托烷司琼后防治恶心的疗效及不良反应比较无显著性差异(P>0.05)。结论:盐酸帕洛诺司琼在防治乳腺癌FEC方案辅助化疗所引起的急性及延迟性呕吐的疗效优于盐酸托烷司琼,且安全性好,值得临床推广。 Objective:Palonosetron hydrochloride and tropisetron hydrochloride were used to prevent the nausea and vomiting caused by breast cancer chemotherapy with cyclophosphamide,pharmorubicin and 5-fluorouracil and the efficacy was investigated.Methods:42 cases with breast cancer receiving chemotherapy with cyclophosphamide,pharmorubicin and 5-fluorouracil after operation were enrolled in this trial.All cases were designed with self-across comparison methods and were randomized into two groups AB group or BA group.Palonosetron hydrochloride was administered to prevent the nausea and vomiting before chemotherapy in AB group when the patients received first course of chemotherapy,tropisetron hydrochloride was administrated during the second course of chemotherapy; On the contrary,tropisetron hydrochloride was administered in BA group when the patients received first course of chemotherapy,palonosetron hydrochloride was administered during the second course of chemotherapy.The situation of nausea and vomiting and adverse reactions were observed and recorded respectively in a period of 4 days after chemotherapy.Results:When palonosetron hydrochloride was administered to prevent the acute vomiting,there were 25 cases with grade 0,13 cases with grade 1,3 cases with grade 2,1 case with grade 3,0 case with grade 4 respectively;while tropisetron hydrochloride was administered to prevent the acute vomiting,there were 21 cases with grade 0,12 cases with grade 1,5cases with grade 2,3 cases with grade 3,1 case with grade 4 respectively;palonosetron hydrochloride was superior to tropisetron hydrochloride in controlling acute vomiting(P〈0.05).When palonosetron hydrochloride was administered to prevent the delayed vomiting,there were 20 cases with grade 0,14 cases with grade 1,7cases with grade 2,1 case with grade 3,0 case with grade 4 respectively;while tropisetron hydrochloride was administered to prevent the delayed vomiting,there were 13 cases with grade 0,15 cases with grade 1,9cases with grade 2,4 cases with grade 3,1
出处 《药物分析杂志》 CAS CSCD 北大核心 2010年第11期2216-2219,共4页 Chinese Journal of Pharmaceutical Analysis
关键词 盐酸帕洛诺司琼 化疗 恶心 呕吐 palonosetron hydrochloride chemotherapy nausea vomiting
  • 相关文献

参考文献7

  • 1Antiemisis from NCCN clinical practice guidelines in cology - version 1. 2005. 被引量:1
  • 2Wiser W, Berger A. Practical management of chemotherapyinduced nausea and vomiting. Oncology(WillistonPark) ,2005,19:637. 被引量:1
  • 3Aapro M. Palonosetron is effective in preventing acute and delayed chemotherapy induced nausea and vomiting in patients recieving highly emetogenic chemotherapy ( HEC ) [ Abstract ]. Support Care Cancer,2003,11 : A17. 被引量:1
  • 4Andrew PLR, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anticancer therapy. Trends in Pharmacol Sci, 1998,9 (9) :334. 被引量:1
  • 5Stoltz R, Cyong JC, Haba, et al. Phannaxokinetic and safety evaluation of palonosetron a 5 - hydroxytryptam ine - 3 receptor antagonist in U. S. and Japanese healthy subjects. J Clin Phamacol 2004,44 (5) :520. 被引量:1
  • 6Hunt TL, Gallagher SC, Cullen MT,et al. Evaluation of safety and pharmacokinetics of consecutive multiple - day dosing of palonosetron in healthy subjects. J Clin Pharmacol,2005,45 (5) :589. 被引量:1
  • 7李志强,徐建明,刘端祺,张贺龙,王宝成,张沂平,欧阳学农,陈正堂,陶敏,高亚杰,王岩,李晓玲,刘烈军.盐酸帕洛诺司琼预防中重度化疗致吐药引起恶心呕吐的Ⅱ期临床研究[J].临床肿瘤学杂志,2009,14(6):487-490. 被引量:36

二级参考文献8

  • 1陈艳,丁莉坤,孟玲燕,丁黎,杨林,文爱东.盐酸帕洛诺司琼注射液人体药动学研究[J].中国新药杂志,2007,16(10):806-809. 被引量:14
  • 2Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase Ⅲ trial comparing single doses of palonosetron with ondansetron [ J ]. Ann Oncol, 2003,14 (10) : 1570 - 1577. 被引量:1
  • 3Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology[ J]. Ther Clin Risk Manag, 2007,3 (6) : 1009 - 1020. 被引量:1
  • 4Siddiqui MA, Scott LJ. Palonosetron [ J ]. Drugs, 2004,64 (10) :1125 - 1132. 被引量:1
  • 5Stohz R, Cyong JC, Shaha, et al. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist,in U. S. and Japanese healthy subjects[J]. J Clin Pharmacol, 2004,44(5 ) :520 -531. 被引量:1
  • 6Eisenberg P, Mackintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study[J]. Ann Oncol, 2004,15(2) :330-337. 被引量:1
  • 7Hunt TL, Gallagher SC, Cullen MT, et al. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects [ J ]. J Clin Pharmacol, 2005,45 (5) :589 -596. 被引量:1
  • 8Aapro MS, Grunberg SM, Manikhas GM, et al. A phase Ⅲ, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy [ J ]. Ann Oncol, 2006,17(9) :1441-1449. 被引量:1

共引文献35

同被引文献9

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部